You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,358,232

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,358,232

Title:	Methods for treating cancer using TOR kinase inhibitor combination therapy
Abstract:	Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide to a patient having a cancer.
Inventor(s):	Hege; Kristen Mae (Burlingame, CA), Chopra; Rajesh (Summit, NJ)
Assignee:	Signal Pharmaceuticals, LLC (San Diego, CA)
Application Number:	14/254,010
Patent Claims:	1. A method for treating diffuse large B-cell lymphoma, comprising administering an effective amount of a TOR kinase inhibitor in combination with an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide, or a pharmaceutically acceptable salt thereof, to a patient having diffuse large B-cell lymphoma, wherein the TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)-pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)- -3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotopologue thereof. 2. The method of claim 1, wherein the diffuse large B-cell lymphoma is associated with the pathways involving mTOR, PI3K, or Akt kinases and mutants or isoforms thereof. 3. The method of claim 1, wherein the TOR kinase inhibitor is administered in combination with a besylate salt of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide. 4. The method of claim 1, wherein the TOR kinase inhibitor is administered in combination with the free base of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide. 5. The method of claim 1, further comprising the administration of an anti-CD20 antibody. 6. The method of claim 5, wherein anti-CD20 antibody is rituximab.

Details for Patent 9,358,232

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2033-04-17
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2033-04-17
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2033-04-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.